Geneoscopy secured FDA approval for an updated stool collection kit for its RNA-based ColoSense colorectal cancer screening test. The new streamlined kit eliminates the need for patients to separate stool samples into multiple containers, a step previously considered burdensome. This improvement aims to enhance patient compliance and screening adherence, thereby potentially improving outcomes. ColoSense targets average-risk individuals aged 45 and older and detects RNA biomarkers linked to cancer and precancerous adenomas. The FDA had approved ColoSense last year, and recent patent rulings have favored Geneoscopy against competitors in stool sample collection techniques.